Paradigm Biopharmaceuticals (ASX:PAR) selected Advanced Clinical as its preferred partner for a phase 3 clinical trial evaluating the dose and treatment effect of injectable pentosan polysulfate sodium in knee osteoarthritis pain, according to a Friday filing with the Australian bourse.
The company expects to receive centralized ethics approval for Australia soon, with the first sites to be activated in Victoria and up to 10 sites across the country, per the filing. The dosing of the first participant is anticipated in the second quarter of the year.
Paradigm Biopharmaceuticals shares rose nearly 4% in midday trade Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.